vascularsolutions
Vascular Solutions can’t dodge illegal marketing lawsuit
Minnesota medical device maker Vascular Solutions (NSDQ:VASC) wasn’t able to dodge a federal off-label marketing lawsuit over its Vari-Lase varicose vein treatment devices, the company revealed in its latest financial report.
FDA makes Vascular Solutions’ catheter valve recall Class I
The FDA slapped its most serious designation on the recall of hemostasis valves made by Vascular Solutions (NSDQ:VASC).
The Minneapolis-based company last month recalled its Guardian II and Guardian II NC valves "due to a risk that air may be introduced into the device which may lead to an air embolism," according to the federal watchdog agency.
Terumo jilts Boston Scientific to launch solo urology unit
Feds join whistleblower probe of Vascular Solutions’ alleged off-label scheme
Vascular Solutions (NSDQ:VASC) is under investigation by the U.S. Attorney’s Office for the Western District of Texas for alleged off-label promotion of its Vari-Lase venous disease treatment system.
Vascular Solutions picks up St. Jude Medical’s Venture catheter for $3M
Vascular Solutions (NSDQ:VASC) said it spent $3 million on the Venture wire control catheter from St. Jude Medical (NYSE:STJ).
Vascular Solutions chief Root laments FDA, taxes, poor education for Minn. med-tech
Vascular Solutions (NSDQ:VASC) CEO Howard Root has much to lament about the state of the medical device industry today.
As a veteran of Minnesota’s medical device body, Root hopes to see the North Star State reverse its recent downward trend in the number of medical device startups and workers.
Zimmer slides on Q1 results | Earnings Roundup
Edwards slides despite “strong” Q4, 2011 results | Earnings Roundup
Shares of Edwards Lifesciences (NYSE:EW) are down more than 6% in after-market trading despite a Wall Street-beating 4th quarter and full year.
Edwards posted profits of $63.1 million, or 53 cents per diluted share, on sales of $430.2 million during the 3 months ended Dec. 31, 2011, representing a sales increase of 9.6% but a bottom-line decline of 2.6%. Excluding 1-time items, EPS reached 62 cents, 3 pennies ahead of expectations on The Street.
Surgical snake maker lands $11.7M in Series C | Funding Roundup
Surgical snake technology developer Medrobotics Corp. closed a $11.7 million Series C funding round led by current shareholders, angel investors and the Pittsburgh Life Sciences Greenhouse.
Medrobotics, originally known as Cardiorobotics, has raised $28.3 million since it spun out of Carnegie Mellon University in 2005.
The Boston, Mass.-based med-tech maker’s robots allow surgeons to perform 2-handed surgeries in hard-to-reach anatomical areas. The robots can support their own weight and move in any 3D space without structural support.
Masimo plunges after missing Q3 earnings target | Earnings Roundup
Shares of Masimo Corp. (NSDQ:MASI) plunged more than 12 percent today after the patient monitoring device maker missed third-quarter earnings expectations and lowered its sales and earnings guidance for the rest of 2011.
MASI shares were trading at $19.61 as of about 1 p.m. today, down 12.1 percent.